Overview

Dr. Eleftheria Hatzimichael has published over 140 peer-reviewed papers across multiple areas of hematology research. The publications span from 1999 to 2025, showing a consistent and productive academic career focusing primarily on hematologic malignancies and disorders.

Key Research Themes

1. Myelodysplastic Syndromes (MDS)

• Treatment Outcomes: Multiple studies on azacitidine therapy in higher-risk MDS patients, analyzing prognostic factors and real-world data through the Hellenic MDS Study Group

• Biomarkers: Identification of serum ferritin and ECOG performance status as predictors of treatment response

• Molecular Pathways: Investigation of microRNAs and epigenetic markers in MDS pathogenesis

• Novel Treatments: Research on luspatercept for MDS-related anemia

Key Papers:

• "Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS" (2023)

• "Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes" (2021)

• "The Role of Non-Coding RNAs in Myelodysplastic Neoplasms" (2023)

2. Lymphomas

• Hodgkin Lymphoma: Studies on the immune microenvironment, autophagy, and cellular senescence in classical Hodgkin lymphoma

• Diffuse Large B-Cell Lymphoma: Research on primary mediastinal large B-cell lymphoma treatments and prognostic factors

• Treatment Responses: Analysis of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma

Key Papers:

• "Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications" (2024)

• "PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?" (2023)

• "Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications" (2023)

3. Multiple Myeloma

• Prognostic Markers: Studies on CD56 expression, methylation patterns, and other markers

• Treatment Outcomes: Real-world data on lenalidomide treatment in relapsed/refractory multiple myeloma

• Elderly Patients: Special focus on octogenarians and treatment approaches

Key Papers:

• "CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome" (2021)

• "Real-life experience with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma" (2014)

• "Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era" (2012)

4. Leukemias

• Chronic Lymphocytic Leukemia: International collaborative studies on treatment strategies

• Acute Myeloid Leukemia: Gene mutations and targeted therapies

• Chronic Myeloid Leukemia: Combination therapy approaches

Key Papers:

• "Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia" (2024)

• "Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy" (2024)

• "Gene mutations and molecularly targeted therapies in acute myeloid leukemia" (2013)

5. Epigenetics in Hematologic Malignancies

• DNA Methylation: Extensive research on methylation patterns in lymphoma, myeloma, and leukemia

• Tumor Suppressor Genes: Investigation of silenced tumor suppressors and their role in disease progression

• Therapeutic Implications: How epigenetic alterations can inform treatment decisions

Key Papers:

• "The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma" (2012)

• "Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease" (2012)

• "Cancer epigenetics: new therapies and new challenges" (2013)

6. Immune Microenvironment

• Immune Evasion: Studies on how malignant cells evade immune responses

• Cytokine Signaling: Extensive work on interleukins and other signaling molecules

• Therapeutic Targeting: Implications for immunotherapy approaches

Key Papers:

• "Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia" (2022)

• "Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases" (2005)

• "Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia" (2001)

7. Novel Therapeutic Approaches

• Targeted Therapies: Research on pacritinib, luspatercept, and other novel agents

• Metronomic Chemotherapy: Studies on alternative dosing strategies

• Treatment of Rare Blood Disorders: Approaches for beta-thalassemia and other rare conditions

Key Papers:

• "Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis" (2022)

• "Profile of pacritinib and its potential in the treatment of hematologic disorders" (2014)

• "Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation" (2016)

Publication Metrics and Collaborations

• Publication Volume: 141 peer-reviewed papers from 1999-2024

• Collaborative Network: Extensive national collaboration through the Hellenic MDS Study Group and Hellenic Cooperative Lymphoma Group

• International Reach: Participation in Europe-wide registries and international multi-center studies

Recent Research Focus (2023-2025)

Recent publications show a continued focus on:

1. Myelodysplastic neoplasms and therapeutic approaches

2. Immune microenvironment in lymphomas

3. Lymphoma treatments and prognostic factors

4. International collaborative studies in chronic lymphocytic leukemia

5. Novel technologies like imaging flow cytometry

Conclusion

Dr. Hatzimichael's research demonstrates a sustained commitment to advancing our understanding of hematologic malignancies, with particular strengths in:

• Translational research connecting molecular findings to clinical applications

• Treatment outcomes and prognostic markers

• Epigenetic mechanisms in blood cancers

• Collaborative clinical research through national and international networks

This body of work has contributed significantly to improved diagnosis, prognostication, and treatment of patients with various blood disorders, particularly myelodysplastic syndromes, lymphomas, and multiple myeloma.